BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BL-5010: Phase I/II data

A single-arm, open-label, German and Dutch Phase I/II trial in 60 patients, showed that BL-1050 met the primary endpoint of safety, with no persistent, irreversible adverse events. A single application of BL-1050 also...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >